+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • September 2021
  • Region: Global
  • DelveInsight
  • ID: 5237647
This “Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Wegener's Granulomatosis/Granulomatosis with Polyangiitis Understanding

Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Overview


Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare multisystem autoimmune disease, characterized by inflammation of small- and medium-sized blood vessels (vasculitis) that results in damage to various organ systems of the body, most often the sinuses, trachea, lungs, and kidneys. The first sign of GPA may be a recurrent respiratory infection, or a cough or runny nose that continues for longer than expected. Other common symptoms of the disease include nosebleeds, joint pain, weakness, tiredness (fatigue), weight loss, or an unexplained fever. The diagnosis of GPA is made based upon a thorough clinical evaluation including routine laboratory tests, a detailed patient history, identification of relevant symptoms, and a variety of specialized tests. The treatment for GPA includes a combination of multiple medications. These medications typically include glucocorticoids such as prednisone and immunosuppressive drugs such as rituximab.

"Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline landscape is provided which includes the disease overview and Wegener's Granulomatosis/Granulomatosis with Polyangiitis treatment guidelines. The assessment part of the report embraces, in depth Wegener's Granulomatosis/Granulomatosis with Polyangiitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wegener's Granulomatosis/Granulomatosis with Polyangiitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Wegener's Granulomatosis/Granulomatosis with Polyangiitis R&D. The therapies under development are focused on novel approaches to treat/improve Wegener's Granulomatosis/Granulomatosis with Polyangiitis.

Wegener's Granulomatosis/Granulomatosis with Polyangiitis Emerging Drugs Chapters


This segment of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wegener's Granulomatosis/Granulomatosis with Polyangiitis Emerging Drugs


Abatacept: Bristol-Myers Squibb


Abatacept, sold under the brand name Orencia, inhibits T cell activation by selectively blocking specific binding of the CD80/CD86 receptor in APC to CD28 on T cells. The pharmacological strategy looks to inhibit the accelerated immune/inflammatory response, characteristic of the disease, and restore normal homeostasis in the immune system. The drug is currently in Phase III clinical studies for the treatment of relapsing, non-severe, granulomatosis with polyangiitis.

Vilobilemab: InflaRx


Vilobelimab (IFX 1; CaCP 29), is an anti-complement C5a monoclonal antibody. The drug is in Phase II clinical studies for the treatment of patients with granulomatosis with polyangiitis. Vilobelimab (IFX-1) holds large potential for treating various inflammatory disease and certain cancers and is in clinical testing for several indications, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangraenosum.

Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Therapeutic Assessment


This segment of the report provides insights about the different Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Wegener's Granulomatosis/Granulomatosis with Polyangiitis


There are approx. 2+ key companies which are developing the therapies for Wegener's Granulomatosis/Granulomatosis with Polyangiitis. The companies which have their Wegener's Granulomatosis/Granulomatosis with Polyangiitis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

Phases


This report covers around 2+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wegener's Granulomatosis/Granulomatosis with Polyangiitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs.

Wegener's Granulomatosis/Granulomatosis with Polyangiitis Report Insights

  • Wegener's Granulomatosis/Granulomatosis with Polyangiitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Wegener's Granulomatosis/Granulomatosis with Polyangiitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs?
  • How many Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wegener's Granulomatosis/Granulomatosis with Polyangiitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wegener's Granulomatosis/Granulomatosis with Polyangiitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Wegener's Granulomatosis/Granulomatosis with Polyangiitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • InflaRx
  • Bristol-Myers Squibb

Key Products

  • Abatacept
  • Vilobilemab
This product will be delivered within 1 business day.

Table of Contents

IntroductionExecutive Summary
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Wegener’s Granulomatosis/Granulomatosis with Polyangiitis - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

Abatacept: Bristol-Myers Squibb
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Vilobilemab: InflaRx
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Wegener’s Granulomatosis/Granulomatosis with Polyangiitis Key CompaniesWegener’s Granulomatosis/Granulomatosis with Polyangiitis Key ProductsWegener’s Granulomatosis/Granulomatosis with Polyangiitis- Unmet NeedsWegener’s Granulomatosis/Granulomatosis with Polyangiitis- Market Drivers and BarriersWegener’s Granulomatosis/Granulomatosis with Polyangiitis- Future Perspectives and ConclusionWegener’s Granulomatosis/Granulomatosis with Polyangiitis Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Wegener's Granulomatosis/Granulomatosis with Polyangiitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Wegener’s Granulomatosis/Granulomatosis with Polyangiitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • InflaRx
  • Bristol-Myers Squibb